• No results found

Relapsed Pediatric Acute Myeloid Leukemia

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.

... when leukemia returned, analysis was performed and residual AML cells con- tinued to express CD33/123, thus concluding that these cells did not develop the resistance mechanisms employed as previously described in ...

13

Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group

Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group

... with relapsed/refractory de novo and secondary AML, with a history of very intensive treatments includ- ing chemotherapy and/or HSCT, that administration of GO on a compassionate use basis was frequently consid- ...

10

MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model

MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model

... The enrichment analysis was performed on all target genes of miR-196b, miR-155 and miR-25. As shown in Figure 3A and 3B, The target genes were significantly enriched in two MetaCore pathways, namely mismatch repair ...

13

Acute Myeloid Leukemia in Pediatric Patients: A Review About Current Diagnostic and Treatment Approaches

Acute Myeloid Leukemia in Pediatric Patients: A Review About Current Diagnostic and Treatment Approaches

... in pediatric AML, myeloablative chemotherapy is preferred over total body irradiation as the latter is associated with an increased risk of secondary malignancies and more late effects ...in pediatric ...

23

Oncologist. The. Pediatric Oncology. Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia

Oncologist. The. Pediatric Oncology. Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia

... Options to intervene in such high-risk patients must be carefully evaluated. Targeted therapies are being developed for patients with FLT3 mutations, but their clinical applica- tions for newly diagnosed patients will ...

15

MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia

MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia

... MLL-rearranged pediatric AML samples (test cohort) and additional eight paired initial diagnosis- relapse samples with MLL-rearrangements (validation cohort) was ...relapse pediatric AML with ...

11

Anti-cancer effects of ginsenoside compound k on pediatric acute myeloid leukemia cells

Anti-cancer effects of ginsenoside compound k on pediatric acute myeloid leukemia cells

... Pediatric acute myeloid leukemia (AML) remains a therapeutically challenging disease, which accounts for 15-20% of all childhood acute leukemia but is responsible for more than ...

6

Acute Myeloid Leukemia

Acute Myeloid Leukemia

... to pediatric patients and older patients who need protection from the toxic effects of excessive anthracycline exposure, which may be damaging to the heart and other ...of relapsed APL patients may develop ...

52

Analysis of BAALC gene Expression as prognosis factor in Pediatric Acute Myeloid Leukemia in Iran

Analysis of BAALC gene Expression as prognosis factor in Pediatric Acute Myeloid Leukemia in Iran

... >20% myeloid blasts in bone marrow aspiration or peripheral blood specimen; 2) attendance of cell surface markers such as CD13, CD33, CD117, CD64, and CD14, recognized by flow cytometery and ...

8

The prevalent predicament of relapsed acute myeloid leukemia

The prevalent predicament of relapsed acute myeloid leukemia

... with acute myeloid leukemia (AML) will relapse after achieving complete ...with relapsed AML should be considered for an appropriate clinical ...

6

Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia

Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia

... One hundred and six patients with de novo pediatric AML were selected from the files of the Department of Pathology, Huai’an First People’s Hospital, China. All the patients were younger than 18 years of age ...

7

Temozolomide and cisplatin in relapsed/refractory acute leukemia

Temozolomide and cisplatin in relapsed/refractory acute leukemia

... had relapsed ALL. Two patients had acute biphe- notypic ...their acute leukemia (range 1–5 ...had relapsed after stem cell trans- plants (1 autologous, 2 ...biphenotypic ...

6

Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia

Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia

... Gemtuzumab ozogamicin, an anti-tumour antibiotic linked to an anti-CD33 antibody (Mylotarg®), has been well studied in AML in adults but to a lesser extent in children. No review has yet been published on the ...

11

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients

... were relapsed patients, and two were patients with first induction therapy resulting in inhibiting no more than 50% of ...were relapsed patients, and five were patients without inhibiting 50% of blasts ...

11

MOLECULAR ASPECTS OF ACUTE MYELOID LEUKEMIA

MOLECULAR ASPECTS OF ACUTE MYELOID LEUKEMIA

... of these is the Wilms’ tumor gene (WT1), which encodes a zinc-finger DNA binding protein. Since it might act as tumor suppressor gene or as onco- gene, functional duality is assumed as it could either be involved in ...

6

Novel agents for acute myeloid leukemia

Novel agents for acute myeloid leukemia

... Abstract: Acute myeloid leukemia (AML) is a complex hematological disease characterized by genetic and clinical heterogeneity. Recent advances in the understanding of AML pathogenesis have paved the ...

18

The epigenetic landscape of acute myeloid leukemia

The epigenetic landscape of acute myeloid leukemia

... in myeloid neoplasm appears to result in reduced H3K27me3 concentrations at specific target loci, perhaps through inhibition of PRC2 recruitment, and consequent overexpression of leukemia-promoting genes [ ...

16

Acute Myeloid Leukemia Research Paper

Acute Myeloid Leukemia Research Paper

... persistent leukemia (PL) rate (7%, 8%, 33%, 14%, 31%), median event-free survival (EFS; 25, 14, 5, 6, 2 months), median overall survival (OS; not reached, 26, 12, 14, 6 months), and median relapse-free survival ...

11

Cytarabine Dose for Acute Myeloid Leukemia

Cytarabine Dose for Acute Myeloid Leukemia

... randomized study showed that four cycles of cy- tarabine at a dose of 3000 mg per square meter given twice daily on days 1, 3, and 5 and admin- istered after complete remission appeared[r] ...

10

Perspectives on the Treatment of Acute Myeloid Leukemia

Perspectives on the Treatment of Acute Myeloid Leukemia

... Outcomes in small studies of adult AML are nearly as good with MUDs as with MRDs; transplant-related mor- tality rates are roughly equivalent based on the center evaluated. As we learn how to separate graft-versus- host ...

14

Show all 10000 documents...

Related subjects